These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37819115)

  • 1. Effect of malate on the activity of ciprofloxacin against
    Bao X; Goeteyn E; Crabbé A; Coenye T
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0068223. PubMed ID: 37819115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organic Acids and Their Salts Potentiate the Activity of Selected Antibiotics against Pseudomonas aeruginosa Biofilms Grown in a Synthetic Cystic Fibrosis Sputum Medium.
    Bao X; Bové M; Coenye T
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0187521. PubMed ID: 34807756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostering Innovation in the Treatment of Chronic Polymicrobial Cystic Fibrosis-Associated Infections Exploring Aspartic Acid and Succinic Acid as Ciprofloxacin Adjuvants.
    Silva E; Monteiro R; Grainha T; Alves D; Pereira MO; Sousa AM
    Front Cell Infect Microbiol; 2020; 10():441. PubMed ID: 32974221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiofilm Activities of Borneol-Citral-Loaded Pickering Emulsions against Pseudomonas aeruginosa and Staphylococcus aureus in Physiologically Relevant Chronic Infection Models.
    Wang W; Bao X; Bové M; Rigole P; Meng X; Su J; Coenye T
    Microbiol Spectr; 2022 Oct; 10(5):e0169622. PubMed ID: 36194139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antibiotic efficacy against infections caused by planktonic or biofilm cultures of Pseudomonas aeruginosa and Klebsiella pneumoniae in Galleria mellonella.
    Benthall G; Touzel RE; Hind CK; Titball RW; Sutton JM; Thomas RJ; Wand ME
    Int J Antimicrob Agents; 2015 Nov; 46(5):538-45. PubMed ID: 26364845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
    VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
    Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
    Millar BC; McCaughan J; Rendall JC; Moore JE
    Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Antibiotics against Pseudomonas aeruginosa in an
    Diaz Iglesias Y; Van Bambeke F
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of N-Acetylcysteine and Antibiotics Against Single and Dual Species Biofilms of Pseudomonas aeruginosa and Achromobacter xylosoxidans.
    Yilmaz FN; Hacioglu M; Aldogan EH
    Curr Microbiol; 2022 Nov; 80(1):5. PubMed ID: 36434296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa.
    Al-Obaidi H; Kalgudi R; Zariwala MG
    Eur J Pharm Biopharm; 2018 Jul; 128():27-35. PubMed ID: 29654885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
    Chang RYK; Das T; Manos J; Kutter E; Morales S; Chan HK
    AAPS J; 2019 Apr; 21(3):49. PubMed ID: 30949776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
    Lu Q; Yu J; Bao L; Ran T; Zhong H
    Chemotherapy; 2013; 59(1):51-6. PubMed ID: 23816803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
    Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
    Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM; Monteiro R; Pereira MO
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM; Hamilton VE; Thomas MR
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.